Recently, VB Media unveiled its 2025 VB100 rankings, with Cygnus Biosciences (Beijing) Co., Ltd. (Cygnus Bio) selected for the “China Innovative Medical Devices and Smart Manufacturing” list in recognition of its proprietary gene sequencing technologies and industry-leading innovations.

First launched in 2015, the VB100 rankings focus on innovative, privately held medical technology companies across China. The initiative seeks to identify high‑potential enterprises in the healthcare sector and catalyze breakthroughs and transformation throughout the industry.

Driven by sustained technological progress, Cygnus Bio has successfully commercialized its S‑series and P‑series gene sequencers. The S‑series GS100 and GS200 sequencers have earned EU CE‑IVDR certification, offering superior performance including high testing speed, reliable data quality, and low operational costs. These systems are widely deployed in pathogen genome sequencing and infectious disease surveillance, delivering strong technical support for public health authorities and customs agencies. Meanwhile, the company’s P‑series GP1000 and GP1000X sequencing platforms deliver single‑run sequencing throughput ranging from 0.3 Tb to 40 Tb.

Against the backdrop of rapid advancement in global gene sequencing technology, Cygnus Bio has built distinct competitive advantages through its proprietary technological ecosystem and consistent R&D investment. Its inclusion in the VB100 list underscores strong market recognition of its technical capabilities and innovative accomplishments.

Looking ahead, Cygnus Bio will continue to deepen its focus on gene sequencing, further increase R&D investment, and accelerate product iteration and technology upgrading. The company will also expand its market reach, strengthen collaboration with upstream and downstream industrial partners, and drive wider adoption of sequencing technology across diverse application scenarios, ultimately advancing the development of life sciences and global public health.